Document 2374
 DOCN  M94A2374
 TI    Disease progression and survival among HIV-infected injecting drug users
       (IDUs) by gender.
 DT    9412
 AU    Brown L; Neaton JD; Wentworth DN; Sherer R; Besch L; Addiction Research
       & Treatment Corp., Brooklyn, NY 11201.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):319 (abstract no. PC0207). Unique
       Identifier : AIDSLINE ICA10/94370201
 AB    OBJECTIVE: To compare HIV disease progression and mortality according to
       gender among HIV-infected injecting drug users (IDU). METHOD: IDUs (370
       females and 999 males) receiving HIV-related primary care at Clinical
       Centers (CC) participating in the Community Programs for Clinical
       Research on AIDS provided demographic and HIV-related clinical
       information at intervals of 6 months or less. Using a proportional
       hazards model, we calculated relative risks (RR) stratified by CC with
       covariates of CD4 count, age, race, Karnofsky score, disease progression
       (DP) history, and use of anti-retroviral (AR) drugs and PCP prophylaxis.
       RESULTS: At study entry, compared to male IDUs, females were more likely
       to be Black (58% vs. 47%), had a higher mean baseline CD4 (319 vs. 240
       cells/cu mm), were less likely to report a prior opportunistic disorder
       (23% vs. 30%), and were less likely to be prescribed AR therapy (56% vs.
       63%) or PCP prophylaxis (37% vs. 53%). Through 9/93, there were 93 DP
       events and 57 deaths among the women compared to 306 and 166,
       respectively, for men. The adjusted RR (women/men) for disease
       progression was 0.95 (95% CI: 0.73-1.22) and for death 1.68 (95% CI:
       1.2-2.35, p < .01). CONCLUSION: These data suggest a greater risk for
       death for women compared to men among IDUs, despite lesser degrees of
       immunosuppression.
 DE    Antiviral Agents/THERAPEUTIC USE  AIDS-Related Opportunistic
       Infections/PREVENTION & CONTROL  Blacks  Female  Human  HIV
       Infections/COMPLICATIONS/DRUG THERAPY/*MORTALITY  Male  Pneumonia,
       Pneumocystis carinii/PREVENTION & CONTROL  Risk Factors  Sex Factors
       Substance Abuse, Intravenous/*COMPLICATIONS  Support, U.S. Gov't, P.H.S.
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).